SLC6A3 and schizophrenia: Further work including study of DAT protein, binding and activity, both in post-mortem and PET imaging studies in the brains of people with schizophrenia (ideally in both medicated and antipsychotic naïve patients and taking into account clinical state such as treatment resistance) compared with controls, are needed to more fully characterize the anatomical sites of DAT abnormalities, especially in the midbrain, and to better understand the implications of our current findings.